Evaluation of Multi-CAR T Cell Therapy Targeting CD7-Positive Blood Cancers in Patients Aged 6 Months to 75 Years

What this Trial Is About

Researchers are evaluating a new CAR T cell therapy targeting CD7-positive hematological malignancies, including T-cell acute lymphoblastic leukemia T-ALL, T cell lymphoma, natural killer cell lymphoma, and acute myeloid leukemia. These diseases can be aggressive and express CD7, a protein important in early T cell development. The study aims to assess the feasibility, safety, and effectiveness of this therapy, as well as to understand how the modified CAR T cells function and persist in patients. The treatment involves genetically modifying T cells from patients or donors with a lentiviral vector to create CD7-specific CAR T cells. These engineered cells are then infused intravenously into patients. This trial uses multiple CAR T cells as a new strategy for treating CD7-positive blood cancers. The study includes a single group receiving this experimental treatment. Participants will be monitored for safety and clinical response over the course of a year after infusion. Assessments include laboratory tests to check organ function, performance status, and disease markers. Researchers will observe the persistence and function of CAR T cells in the body. The entire study period extends until the end of 2030, with ongoing follow-up to evaluate outcomes and safety.

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies